LON:RENX Renalytix (RENX) Share Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free RENX Stock Alerts GBX 27.75 -0.25 (-0.89%) (As of 05/3/2024 04:17 PM ET) Add Compare Share Share Today's Range 27▼ 3050-Day Range 21.50▼ 50.4052-Week Range 10▼ 150Volume501,997 shsAverage Volume575,930 shsMarket Capitalization£33.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Renalytix alerts: Email Address Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Renalytix Stock (LON:RENX)Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More RENX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RENX Stock News HeadlinesMarch 9, 2024 | uk.finance.yahoo.comIs Renalytix the best penny stock to buy today?February 17, 2024 | finance.yahoo.comRNLX Mar 2024 2.500 callMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” February 15, 2024 | finanznachrichten.deRenalytix plc: Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024February 15, 2024 | uk.investing.comRenalytix AI plc (RENX)February 14, 2024 | nz.finance.yahoo.comRenalytix Plc (RNLX) stock price, news, quote & history – Yahoo FinanceFebruary 13, 2024 | morningstar.comRenalytix PLC RENXFebruary 13, 2024 | uk.finance.yahoo.comAfter the Renalytix share price jumps 500% in 3 days, is it time to buy?May 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” January 10, 2024 | finanznachrichten.deRenalytix plc: New published data demonstrates KidneyIntelX has broad implications for winning war on chronic kidney diseaseNovember 15, 2023 | benzinga.comRenalytix Stock (NASDAQ:RNLX) Earnings Dates and Earning CallsSeptember 28, 2023 | markets.businessinsider.comRenalytix Reports Full Year Fiscal 2023 ResultsSeptember 7, 2023 | finance.yahoo.comRenalytix Appoints Senior Executive Howard Doran as Chief Business OfficerJuly 3, 2023 | finance.yahoo.comRenalytix Appoints Financial Executive Catherine Coste to its Board of DirectorsJune 29, 2023 | finance.yahoo.comFDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney DiseaseJune 15, 2023 | finance.yahoo.comKidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific ConferencesMay 31, 2023 | uk.movies.yahoo.comIs the Renalytix share price a bargain or a falling knife?April 20, 2023 | marketwatch.comNew Published Real-World Evidence Shows KidneyIntelX(TM) UtilityApril 19, 2023 | finance.yahoo.comNew Published Real-World Evidence Shows KidneyIntelX™ UtilityApril 12, 2023 | finance.yahoo.comData Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical MeetingMarch 30, 2023 | finance.yahoo.comRenalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial ResultsMarch 21, 2023 | marketwatch.comRenalytix Shares Fall on Delay to FDA Marketing Authorization Decision on KidneyIntelXFebruary 9, 2023 | finance.yahoo.comRenalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 8, 2023 | finance.yahoo.comRenalytix announces a c.$20.3 million private placementJanuary 26, 2023 | marketwatch.comRenalytix Shares Rise on $10 Mln Grant Award to Advance Chronic Kidney Disease TreatmentJanuary 26, 2023 | finance.yahoo.comRenalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United StatesJanuary 9, 2023 | finance.yahoo.comRenalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systemsSee More Headlines Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:RENX CUSIPN/A CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-41,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-651.40% Return on Assets-88.32% Debt Debt-to-Equity Ratio173.95 Current Ratio0.59 Quick Ratio2.42 Sales & Book Value Annual Sales£2.41 million Price / Sales13.81 Cash FlowGBX 15.12 per share Price / Cash Flow1.84 Book ValueGBX (8) per share Price / Book-3.47Miscellaneous Outstanding Shares119,920,000Free FloatN/AMarket Cap£33.28 million OptionableNot Optionable Beta1.92 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. James R. McCullough M.B.A. (Age 56)Chief Executive Officer Comp: $820.68kMr. Thomas H. McLain CPA (Age 65)M.B.A, President Comp: $524.8kMr. Oliver James Sterling IIIChief Financial OfficerMr. Fergus Fleming (Age 56)Chief Technology Officer Dr. Michael J. Donovan M.D. (Age 69)Ph.D., Chief Medical Officer Mr. Howard B. Doran Jr. (Age 63)Chief Business Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryMore ExecutivesKey CompetitorsCambridge CognitionLON:COGFeedbackLON:FDBKInduction Healthcare GroupLON:INHCOKYO PharmaLON:OKYOIntelligent Ultrasound GroupLON:IUGView All Competitors RENX Stock Analysis - Frequently Asked Questions How have RENX shares performed in 2024? Renalytix's stock was trading at GBX 15.50 on January 1st, 2024. Since then, RENX shares have increased by 79.0% and is now trading at GBX 27.75. View the best growth stocks for 2024 here. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include United Microelectronics (UMC), Teva Pharmaceutical Industries (TEVA), SSP Group (SSPG), Sarepta Therapeutics (SRPT), Redrow (RDW), QUALCOMM (QCOM), Lloyds Banking Group (LLOY), Entain PLC (GVC.L) (GVC), Gamma Communications (GAMA) and eHealth (EHTH). How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:RENX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
